Lexaria Oral Nicotine Study Begins Dosing

Lexaria Bioscience, (Nasdaq: LEXX) has begun dosing subjects in an oral nicotine study that will compare DehydraTECH-nicotine pouch performance to existing leading brands ON!, manufactured by Altria, and Zyn, manufactured by Swedish Match.


  • Lexaria’s study is a 36-person human pharmacokinetic randomized, double blinded, cross-over study conducted in current cigarette smokers.
  • Each volunteer will visit the laboratory three times to be dosed.
  • Dosing will evaluate DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match.
  • In March 2022, Lexaria received its first ever patent granted to use DehydraTECH to more efficiently deliver nicotine through buccal tissue absorption.
  • The study is fully funded from internal company resources.

The oral nicotine pouch category is one of the fastest growing segments of the nicotine industry due to their status as modified risk tobacco products. The global market for the oral nicotine pouch category is expected to reach $21.84 billion in 2027.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lexaria Oral Nicotine Study Begins Dosing

Editor Prism MarketView